



Original article

Evaluation of drug-induced liver injury as etiology for acute liver failure in Brazil



Genario Santos^{a,*}, Estela Regina Ramos Figueira^b, Luiz Augusto Carneiro D'Albuquerque^b, Paulo Bittencourt Lisboa^c, Marcio Dias de Almeida^d, Norma Arteiro Filgueira^e, Ilka Boin^f, Gilda Porta^g, Rita de Cássia Martins Alves da Silva^h, Cyntia Ferreira Gomes Vianaⁱ, Luciana Costa Faria^j, Mario Reis Alvares-da-Silva^k, Adriano Claudio Pereira de Moraes^l, Daphne Benatti Goncalves Morsoletto^m, Liana Codes^c, Raymundo Paraná^a

^a Health Science Postgraduation, Faculty of Medicine, University Federal of Bahia, Brazil

^b Department of Gastroenterology, Division of Digestive Surgery, Hospital das Clínicas of University of São Paulo School of Medicine, São Paulo, Brazil

^c Unit of Gastroenterology and Hepatology, Portuguese Hospital, Salvador-BA, Brazil.

^d Albert Einstein Israelite Hospital, São Paulo, Brazil

^e Department of Internal Medicine, University Federal of Pernambuco, Brazil

^f Medical Sciences Faculty of Campinas State University, Campinas, São Paulo, Brazil

^g Department of Pediatrics, Children's Institute, Medical School of the University of São Paulo, São Paulo, Brazil

^h São José do Rio Preto Medical School (FAMERP), São José do Rio Preto- SP, Brazil

ⁱ Liver Transplant Center of Ceara, Walter Cantídio University Hospital, Fortaleza- CE, Brazil

^j Department of Internal Medicine, Federal University of Minas Gerais, School of Medicine, Belo Horizonte-MG, Brazil

^k Gastroenterology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre - RS, Brazil

^l Unit of Liver Transplantation, Cardiology Institute of Federal District, Federal District, Brazil

^m Nossa Senhora das Graças Hospital, Curitiba - PR, Brazil

ARTICLE INFO

Article history:

Received 15 October 2020

Accepted 11 December 2020

Available online 27 January 2021

Keywords:

Drug induced liver injury

Acute liver failure

Liver injury

ABSTRACT

Introduction and objectives: Little is known about the etiology of acute liver failure (ALF) in Latin America. The objective of this paper is to investigate the main etiologies of ALF in Brazil, including Drug Induced Liver Injury (DILI) using stringent causality criteria.

Patients or material and methods: All the cases of individuals who underwent liver transplantation (LT) in 12 centers in Brazil for ALF were reviewed. When DILI was stated as the cause of ALF, causality criteria were applied on site by the main investigator in order to rule out other etiologies.

Results: 325 individuals had ALF mainly for unknown reasons (34%), DILI (27%) and AIH (18%). Reassessment of the 89 cases of DILI, using stringent causality criteria, revealed that in only 42 subjects could DILI be confirmed as the cause of ALF. Acetaminophen (APAP) toxicity (n = 3) or DILI due to herbal and dietary supplements (HDS) (n = 2) were not commonly observed.

Conclusions: Undetermined etiology and DILI are the main causes of ALF in Brazil. However, APAP toxicity and DILI due to HDS are mostly uncommon.

© 2021 Published by Elsevier España, S.L.U. on behalf of Fundación Clínica Médica Sur, A.C. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Abbreviations: ALF, Acute liver failure; DILI, Drug induced liver injury; LT, Liver transplantation; AIH, Autoimmune hepatitis; APAP, Acetaminophen; HDS, Herbal and dietary supplements; HE, Hepatic encephalopathy; CLD, Chronic liver disease; HAV, Hepatitis A viruses; HBV, Hepatitis B viruses; HEV, Hepatitis E viruses; AFLP, Acute fatty liver in pregnancy; WD, Wilson disease; TMC, Traditional Chinese medicine; Anti-TB, Anti-tuberculous; PI, Principal investigator; IND-ALF, Undetermined acute liver failure; DILI-ALF, Drug induced liver injury - acute liver failure; AIH-ALF, Autoimmune acute liver failure.

* Corresponding author at: Prof. Edgard Santos University Hospital of the Federal University of Bahia, Dr. Augusto Viana Street, Canela, 40110060 Salvador, Bahia, Brazil.

E-mail addresses: genariofarma@yahoo.com.br (G. Santos), estelafigueira@me.com (E.R.R. Figueira), contato@professorluizcarneiro.com.br (L.A.C. D'Albuquerque), plbbr@me.com (P.B. Lisboa), marcio.almeida@einstein.br (M.D. de Almeida), norma.arteiro@hotmail.com (N.A. Filgueira), ilkaboin@yahoo.com (I. Boin), gildaporta@gmail.com (G. Porta), ritasilva50@gmail.com (R.d.C.M.A. da Silva), cyntiaviana@menescal.net (C.F.G. Viana), lucostafaria@hotmail.com (L.C. Faria), marioreis@live.com (M.R. Alvares-da-Silva), dr.adrianomoraes@hotmail.com (A.C.P. de Moraes), daphne.bgm@gmail.com (D.B.G. Morsoletto), lianacodes@uol.com.br (L. Codes), unif@svn.com.br (R. Paraná).

<https://doi.org/10.1016/j.aohep.2021.100310>

1665-2681/© 2021 Published by Elsevier España, S.L.U. on behalf of Fundación Clínica Médica Sur, A.C. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Acute liver failure (ALF) is a life-threatening potentially reversible disorder characterized by severe liver damage leading to hepatic encephalopathy (HE) and, within days to a few weeks, to the decease of patients with no previous history of chronic liver disease (CLD) [1]. It can be caused by viral hepatitis, particularly hepatitis A (HAV), B (HBV) and E (HEV) viruses; an intentional or unintentional overdose with acetaminophen (APAP); drug-induced liver injury (DILI); other diseases such as Budd-Chiari syndrome (BCS), malignancy, HELLP syndrome and acute fatty liver of pregnancy (AFLP) [1–3]. Some CLD such as autoimmune hepatitis (AIH) and Wilson disease (WD) may present ALF without any previous warning sign of liver disease and are also included in the clinical spectrum of ALF [3]. Undetermined etiology is responsible for 17%–38% of the cases of ALF [1].

There is a significant geographic heterogeneity with respect to the etiology of ALF worldwide [1]. APAP overdose is the most common cause in United States of America (USA) and United Kingdom, whereas HBV and HEV infections are the main causes of ALF in Asia and Africa [1,4]. APAP toxicity is responsible for 39%–57% of the cases of ALF in the USA and the UK, while DILI is responsible for 11%–14% of the cases of ALF usually ascribed to the use of antibiotics, herbal and dietary supplements (HDS), cardiovascular and central nervous system agents in the USA and HDS and traditional chinese medicine (TCM) and antituberculous (anti-TB) drugs in China [4–6]. Undetermined etiology is reported more frequently in Africa and Asia compared to North America and Europe.

Little is known about the epidemiology of ALF in Latin America [7]. According to an article, the most common etiologies reported were undetermined, AIH and HBV infection. Few cases were attributed to an APAP overdose or DILI and none to HDS.

There is increasing concern regarding the emergence of HDS as an important cause of ALF around the world, due to its widespread use by the general population. Recent studies have reported that 4% to 20% of all cases of DILI in Europe and USA and 26% of those in China can be ascribed nowadays to HDS [5,6,8]. The role of HDS in DILI leading to ALF in other parts of the world is currently unknown.

The purpose of the present study is to investigate the main causes of ALF leading to liver transplantation (LT) in Brazil as well as to investigate the role of APAP toxicity and DILI in the development of ALF using stringent criteria.

2. Patients and methods

All liver transplant centers in Brazil, which had performed more than 100 surgical procedures in the last 5 years, according to the Brazilian Transplant Registry, were invited to take part in the study that was sponsored by the Brazilian Society of Hepatology. After participation agreement, each center answered a survey drawn up by the principal investigator (PI), concerning the number of LTs performed and etiology of all the cases of ALF reported by each center. Etiology of ALF was determined by the local investigator. All cases which had ALF as defined by Trey and Davidson and met prioritization criteria according to Clichy or Kings College Hospital to be eligible for LT, according to the Brazilian policy regarding organ transplantation at that time [9–11], were included in the study. All cases suspected of DILI and APAP overdose were further evaluated by the central PI, who visited each LT center to review patient files and laboratory and explant pathology results in order to confirm DILI or HDS as the cause of ALF. The causality assessment was performed according to established international criteria, according to the Roussel Uclaf Causality Assessment Method (RUCAM) for evaluating the likelihood that a medication is the subjacent cause of DILI [12].




Fig. 1. Etiology of ALF in Brazil determined by site main investigators. APAP: acetaminophen, AFLP: acute fatty liver of pregnancy, BCS: Budd-Chiari syndrome, AIH: autoimmune hepatitis, WS: Wilson disease, DILI: drug induced liver injury.

Briefly, the presence of at least three of the first four parameters, including time from drug intake and withdrawal to the apparent onset of the reaction, course of reaction after cessation of the drug and exclusion by detailed investigation of alternate etiologies had to be present in order to ascertain the occurrence of drug-related ALF. Due to the nature of the present investigation, positive rechallenge response was not taken into account. This study was approved by the Ethics Committee of the University Hospital of Bahia, Brazil. Data in the text and tables are expressed as means and standard deviation.

3. Results

Twelve LT centers in different parts of the country agreed to take part in the study. They had performed 6030 LT procedures in adult and pediatric patients between January 1, 2006 and October 31, 2015. Three hundred and twenty five patients (5.4%), including 297 adults and 28 children, underwent transplants due to ALF.

The etiology of ALF in these patients is presented in Fig. 1. The majority of the cases were undetermined (IND-ALF) (34%), either DILI (DILI-ALF) or APAP toxicity (27%) and AIH (AIH-ALF) (18%) ALF. DILI was the most common cause of ALF in certain states of Brazil, particularly the Southern and Southeastern.

Further investigation of these 89 subjects with presumed ALF due to DILI (n = 84) or APAP toxicity (n = 5) by the central PI revealed that only 42 (47%), 40 adults and 2 children, had clear-cut criteria for DILI after a detailed review of patient files, laboratory and histology data. Clinical and laboratory data of these patients (37 females, mean age 35 + 15 years) are shown in Table 1. Hepatocellular liver injury (76%) was more prevalent, as expected. Nineteen (45%) patients survived more than one year after LT. Most of the deaths (n = 23) occurred within the first eight days after transplantation.

The most common causes of drug-related ALF were: anti-TB drugs (21%), including isoniazid, rifampicin and pyrazinamide combination and non-steroidal anti-inflammatory drugs (21%), including diclofenac (n = 5), nimesulide (n = 3) and paracetamol (n = 1); antibiotics (19%), including sulfamethoxazol and trimethoprim combination (n = 2) and one each for ciprofloxacin, amoxicillin,

Table 1

Clinical and laboratory features of those patients with drug-related DILI leading to ALF (n = 42).

Age (years)	35 ± 15
Female sex	37 (86%)
Body mass index (kg/cm ²)	25 ± 5
INR	4,6 ± 2,9
Total bilirubin (mg/dL)	22 ± 16
Alanine aminotransferase (U/L)	1616 ± 1960
Aspartate aminotransferase (U/L)	2425 ± 2713
Hepatocellular liver injury	32 (76%)
Mixed hepatocellular and cholestatic liver injury	10 (24%)
Hypersensitivity features ^a	4 (10%)
1-year Survival	19 (45%)

ULN: upper limit of normal; INR: international normalized ratio.

^a Including skin rash, fever, lymphadenopathy and/or eosinophilia.

nitrofurantoin, minocycline, imipenem and sulfasalazine; methyltopa (n = 3). Other agents (one each) implicated in DILI-ALF were phenytoin, venlafaxine, duloxetine, carbamazepine, imatinib, methotrexate, propylthiouracil and halothane. HDS was rare due to tea infusions of *Bidens pilosa* (n = 1) and *Ruellia bahiensis* (n = 1). APAP toxicity was confirmed in only 3 individuals, however, in only one it was used in a suicide attempt. More than one drug was responsible for ALF in 30% of the cases.

4. Discussion

The present study found out that 5.4% of the LTs performed in the 12 transplantation centers were due to ALF. This corroborates previous research which found that 6% of the indications for LT in Brazil were due to ALF [13]. The main causes for ALF reported by the PI were IND-ALF, DILI-ALF and AIH-ALF, which were much more frequent when compared to ALF due to viral hepatitis and APAP. Surprisingly, HDS were an uncommon trigger for DILI-ALF. IND-ALF was also reported as the most common cause for ALF in Africa, India and Japan [1], which may reflect a lack of resources for adequate laboratory investigation or the presence of unrecognized local triggers for acute liver injury. In this regard, undetermined etiology was shown to be responsible for only 11% of the causes of ALF in USA [4]. Reassessment of 303 North American patients with IND-ALF, with further determination of APAP protein adducts and additional serological and molecular analysis for viruses in stored sera, reassigned a definite etiology for ALF in 47% of those cases, including APAP toxicity (15%), AIH-ALF (11%) and DILI-ALF (8%). It is therefore possible that some of our cases of IND-ALF could be also reassigned to other etiologies if we had employed a similar strategy.

However, more than half of the patients with APAP or DILI-ALF reported by the PI had to be reassigned to undetermined etiology because they did not meet the predefined established causality criteria for DILI after extensive data review. In spite of this, it is important to highlight that some of the subjects could really have had DILI-ALF. This is due to the fact that it is almost impossible to comply with some of the aforementioned criteria in the setting of urgent LT for ALF, because there is often no time to evaluate the course of liver enzyme reactions after drug withdrawal and no feasibility for drug rechallenge.

It is important to highlight that AIH was the third cause of ALF identified in Brazil, but this corroborates previous data showing that the disease affects mainly children and its presentation in Brazil is more severe when compared to North-America [14]. In Argentina, AIH was also one of the leading causes of ALF. It is worth mentioning that, in both countries, pediatric AIH is associated with similar HLA-DRB1 alleles, namely HLA-DRB1*1301 [15].

DILI was the second most frequent etiology for ALF in the present cohort and was commonly associated with anti-TB drugs, NSAIDs

and antibiotics but, surprisingly, HDS was associated with ALF in just 3 patients, as well as APAP toxicity. Two compounds, *Bidens pilosa* and *Ruellia bahiensis* were associated with DILI-ALF. Hepatotoxicity due to *Ruellia bahiensis* leading to ALF in the same patients have been previously reported, but not DILI-ALF due to *Bidens pilosa* [16]. Both are herbal compounds commonly used for tea infusions. However, both etiologies could be responsible for at least some cases of IND-ALF as patients tend not to report the use of HDS because they are generally considered safe by the majority of the population. Our results were also similar to those reported by Argentina, where undetermined etiology, AIH, HBV and DILI were the most common causes of ALF [7]. Similar to our findings, APAP toxicity was rare, reported in only two Argentinian patients. On the other hand, viral hepatitis was not a significant cause of ALF in Brazil, probably due to the decline in the incidence of HAV and HBV infections in the country owing to universal vaccination as well as the rarity of cases of hepatitis E in Brazil according to seroprevalence studies [17–19]. Mortality was higher than expected, probably due to a shortage as well as late prioritization of organs for ALF.

In summary, most of the cases of ALF in Brazil were linked to undetermined etiology, DILI and AIH. Reassessment of the cases of DILI-ALF revealed that more than 50% of these patients did not meet the stringent criteria of causality. AIH is a relevant cause of ALF in the country which is probably related to a more severe disease presentation in Latin America.

Patient consent statement

Not required by the Ethics Committee due to the methodology and retrospective nature of the investigation.

Funding statement

The present study has been supported by grants of the Johnson & Johnson Foundation (Number 1321/11). And Maria Emilia Pedreira Freire de Carvalho Foundation, Brazil (CONV 7/2016 Number: 23066015723/16-10).

This funding sources had no involvement in the study design; in the collection analysis, and interpretation of data; in the writing of the report or in the decision to submit the manuscript for publication.

Ethics approval statement

This study was approved by the Ethics Committee of the University Hospital of Bahia, Brazil. CAAE number: 46361615.1.1001.0049.

Conflict of interest disclosure

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Permission to reproduce material from other sources

None.

References

- [1] Bernal W, Wendon J. Acute liver failure. *N Engl J Med* 2013;369(26):2525–34. <http://dx.doi.org/10.1056/NEJMra1208937>.
- [2] Wendon J, Cordoba J, Dhawan A, Larsen FS, Manns M, Samuel D, et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. *J Hepatol* 2017;66(5):1047–81. <http://dx.doi.org/10.1016/j.jhep.2016.12.003>.

- [3] Polson J, Lee WM, American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. *Hepatology* 2005;41:1179–97, <http://dx.doi.org/10.1002/hep.20703>.
- [4] Ganger DR, Rule J, Rakela J, Bass N, Reuben A, Stravitz RT, et al. Acute liver failure of indeterminate etiology: a comprehensive systematic approach by an expert committee to establish causality. *Am J Gastroenterol* 2018;113(9):1319, <http://dx.doi.org/10.1038/s41395-018-0160-2>.
- [5] Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. United states drug induced liver injury network. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. *Gastroenterology* 2015;148(7):1340–52, <http://dx.doi.org/10.1053/j.gastro.2015.03.006>.
- [6] Shen T, Liu Y, Shang J, Xie Q, Li J, Yan M, et al. Incidence and etiology of drug-induced liver injury in Mainland China. *Gastroenterology* 2019;156(8):2230–41, <http://dx.doi.org/10.1053/j.gastro.2019.02.002>.
- [7] Mendizabal M, Tagliafichi V, Rubinstein F, Rojas P, Marciano S, Yantorno S, et al. Liver transplantation in adults with acute liver failure: outcomes from the Argentinean Transplant Registry. *Ann Hepatol* 2019;18(2):338–44, <http://dx.doi.org/10.1016/j.aohp.2018.11.003>.
- [8] Medina-Caliz I, Garcia-Cortes M, Gonzalez-Jimenez A, Cabello MR, Robles-Diaz M, Sanabria-Cabrera J, et al. Herbal and dietary supplement-induced liver injuries in the spanish DILI registry. *Clin Gastroenterol Hepatol* 2018;16(9):1495–502, <http://dx.doi.org/10.1016/j.cgh.2017.12.051>.
- [9] Trey C, Davidson CS. The management of fulminant hepatic failure. *Prog Liver Dis* 1970;3:282–98.
- [10] O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. *Gastroenterology* 1989;97:439–45, [http://dx.doi.org/10.1016/0016-5085\(89\)90081-4](http://dx.doi.org/10.1016/0016-5085(89)90081-4).
- [11] Bernuau J, Samuel D, Durand F. Criteria for emergency liver transplantation in patients with acute viral hepatitis and factor V below 50% of normal: a prospective study. *Hepatology* 1991;14, 49A.
- [12] Aithal P, Day C. The natural history of histologically proved drug induced liver disease. *Gut* 1999;44(5):731–5, <http://dx.doi.org/10.1136/gut.44.5.731>.
- [13] Bittencourt PL, Farias AQ, Couto CA. Liver transplantation in Brazil. *Liver Transpl* 2016;22(9):1254–8, <http://dx.doi.org/10.1002/lt.24487>.
- [14] Czaja AJ, Souto EO, Bittencourt PL, Cancado EL, Porta G, Goldberg AC, et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. *J Hepatol* 2002;37(3):302–8, [http://dx.doi.org/10.1016/S0168-8278\(02\)00182-4](http://dx.doi.org/10.1016/S0168-8278(02)00182-4).
- [15] Czaja AJ. Global disparities and their implications in the occurrence and outcome of autoimmune hepatitis. *Dig Dis Sci* 2017;62(9):2277–92, <http://dx.doi.org/10.1007/s10620-017-4675-y>.
- [16] Santos Gasca J, Parana R, Nunes V, Schinnoni M, Medina-Caliz I, et al. Profile of herbal and dietary supplements induced liver injury in Latin America: a systematic review of published reports. *Phytother Res* 2020;06(11):1–14, <http://dx.doi.org/10.1002/ptr.6746>.
- [17] De Oliveira TM, Vieira NSG, Sepp TDS, Souto FJD. Recent trends in hepatitis A incidence in Brazil. *J Med Virol* 2020;92:1343–9, <http://dx.doi.org/10.1002/jmv.25694>.
- [18] Souto FJ. Distribution of hepatitis B infection in Brazil: the epidemiological situation at the beginning of the 21st century. *Rev Soc Bras Med Trop* 2016;49:11–23, <http://dx.doi.org/10.1590/0037-8682-0176-2015>.
- [19] Tengan FM, Figueiredo GM, Nunes AKS, Manchiero C, Dantas BP, Magri MC, et al. Seroprevalence of hepatitis E in adults in Brazil: a systematic review and meta-analysis. *Infect Dis Poverty* 2019;8(1):3, <http://dx.doi.org/10.1186/s40249-018-0514-4>.